Blood eosinophils might finally tell doctors which bronchiectasis patients actually benefit from inhaled steroids, and which ones just get pneumonia.
A systematic review published in Cureus on November 4 combed through every peer‑reviewed study that compared inhaled corticosteroid outcomes across eosinophil strata in adults with non‑cystic fibrosis bronchiectasis. The verdict: the evidence is still too thin, too inconsistent, and too tangled with COPD overlap to change prescribing habits — yet.
International guidelines restrict routine ICS use in bronchiectasis to patients who also have asthma, COPD, or allergic bronchopulmonary aspergillosis. A Cochrane review found no overall benefit in unselected bronchiectasis patients. Yet registry data show ICS remain among the most prescribed maintenance drugs, often without a guideline‑concordant indication, and their immunosuppressive effects raise red flags in a disease driven by chronic bacterial infection.
The review’s authors — led by researchers who searched PubMed, Google Scholar, and citation trails through November 4, 2026 — found fewer than ten eligible studies.
Because the studies used different eosinophil thresholds (percentages, absolute counts, lab upper limits), different comparators, and different outcomes (exacerbations, pneumonia, lung function, mortality), a meta‑analysis was impossible. They synthesized results narratively, grouping by outcome and by population: bronchiectasis without ICS‑responsive comorbidities, bronchiectasis‑COPD overlap, and mixed cohorts.
In a European multicohort study, roughly 20 % of non‑asthmatic bronchiectasis patients had blood eosinophil counts ≥300 cells/µL, and those patients had a shorter time to next exacerbation after adjusting for infection. But prognosis is not prediction.
Post‑hoc analyses of fluticasone trials hinted at quality‑of‑life improvement and fewer exacerbations in eosinophilic patients, while a budesonide trial analysis found no such signal. Observational studies have been similarly split, with some reporting infection‑related harms in low‑eosinophil subgroups.
“The COPD playbook — where eosinophils guide ICS decisions — doesn’t translate cleanly,” said a co‑author of the review. “In bronchiectasis you have neutrophilic inflammation, chronic Pseudomonas, and structural damage all at once. A single blood count can’t capture that complexity.”
The review scored included studies with selection (maximum four stars), comparability (maximum two stars), and outcome or exposure (maximum three stars) domains. Total scores of 7-9 were considered good quality, 5-6 moderate quality, and ≤4 poor quality. Not a single study reported a formal treatment‑by‑biomarker interaction test — the gold standard for proving effect modification.
For the estimated 566 per 100,000 women and 486 per 100,000 men living with bronchiectasis in the U.K. alone — numbers that have risen sharply since 2004 — the stakes are concrete. Every unnecessary ICS prescription adds pneumonia risk without proven exacerbation reduction. Every missed opportunity to target a true eosinophilic responder leaves a patient cycling through antibiotics and hospital admissions.
“We’re not saying stop checking eosinophils,” a co-author told Cureus. “We’re saying don’t let the number write the prescription until the evidence catches up.”